Nuvectis Pharma Reports Third-Quarter Net Loss of $30.1 Million
Nuvectis reported a $30.1 million net loss attributable to common shareholders in the third quarter of 2026, versus a $7.5 million loss a year earlier. Revenue was zero in both periods, and loss per share widened to $1.02 from $0.44.
Nuvectis Pharma, Inc. reported a net loss attributable to common shareholders of $30.1M for the third quarter of 2026, compared with a $7.5M loss in the prior-year quarter. The company reported no revenue in either period, while loss per share widened to $1.02 from $0.44.Financial HighlightsBusines…